Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gopa Iyer

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
European Urology|February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Nature Communications|November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancerJeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
The Journal of Pathology|September 5, 2023
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinomaRami S Vanguri, James W Smithy, Yanyun Li, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
The Journal of Pathology|March 7, 2019
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladderSumit Isharwal, Wenhuo Hu, Judy Sarungbam, et al.
Clinical Genitourinary Cancer|May 30, 2026
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing SchedulesMichal Sternschuss, Charlie White, Colleen Quinlan, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
European Urology|February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
Nature Communications|November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancerJeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
The Journal of Pathology|September 5, 2023
Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinomaRami S Vanguri, James W Smithy, Yanyun Li, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
The Journal of Pathology|March 7, 2019
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladderSumit Isharwal, Wenhuo Hu, Judy Sarungbam, et al.
Clinical Genitourinary Cancer|May 30, 2026
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing SchedulesMichal Sternschuss, Charlie White, Colleen Quinlan, et al.
Case Reports in Oncology|April 1, 2021
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportBrendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Pageof 15